Furthermore, our results show that BAG3 is required for maintaining sarcomere proteostasis and optimal tension generation in cardiomyocytes and demonstrate that the potential therapeutic benefits of BAG3 gene therapy in heart failure include improving myofilament function by restoring sarcomeric protein turnover. This evidence concerns the gene BAG3 and heart failure.